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Betalactams are the most widely utilized drugs against infections but are the primary cause of allergic reactions to 
antibiotic drugs. REF1 An accurate diagnosis of these allergic reactions to betalactams is crucial to avoid the use of 
unnecessary alternative antibiotics that may reduce efficacy, lead to prolonged treatments, have a higher toxicity or induce 
bacterial resistance. The most consensual approach to diagnose betalactam allergy are in vivo tests. However, they are not 
risky free, require experienced personnel and are both time-consuming and expensive for health-care systems, being so in 
vitro test more appropriate or complementary to the in vivo tests. In vitro tests are not still widely used on account of their 
low sensitivity. Current efforts are in progress to improve these assays, thus allowing for better diagnosis of allergic responses 
within patients. REF 2 
We report progress in the preparation of new functional materials for in vitro allergic diagnosis testing. In particular, 
the application of new approaches employing orthogonally functionalised fluorescent dyes based upon 4-amino-1,8 
naphthalimide joined with the multivalence of polyamide dendrimers. REF 3 The in vitro diagnosis capabilities of these 
functional materials was verified by testing on patient sera samples, with results demonstrating their potential for application 
within the healthcare industry. 
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